Public Reporting Information

For general questions or additional information about Accountable Care Organizations, please visit www.medicare.gov/acos.html or call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048. 

The Hackensack Alliance ACO provides the following information in accordance with Medicare Shared Savings Program (MSSP) regulations at 42 CFR §425.308.

ACO Name and Location
Name: Hackensack Physician-Hospital Alliance ACO, LLC (dba Hackensack Alliance ACO)
Location: Hackensack Meridian Health – 30 Prospect Avenue – 3 St. John Room 3844 – Hackensack, NJ 07601
Email: ACOInfo@HackensackMerdian.org

ACO Primary Contact
Name: Morey Menacker, DO
Email: Morey.Menacker@HackensackMeridian.org
Telephone: 551-996-4330
Facsimile: 551-996-0801

ORGANIZATIONAL INFORMATION

ACO Participants:

  1. ALLAM MEDICAL GROUP LLC
  2. FEI YU
  3. FOREST HEALTHCARE ASSOCIATES, PC
  4. FRANK MASTRIANNO
  5. GARY SCHWARTZ MD
  6. HACKENSACK UNIVERSITY MEDICAL GROUP PC
  7. INTEGRATED MEDICAL ASSOCIATES LLC
  8. LHP NEW JERSEY MD SERVICES PC
  9. MAGED BOUTROS
  10. MEDICAL ASSOCIATES OF ENGLEWOOD PC
  11. MONTCLAIR HOSPITAL LLC
  12. MOUNTAINVIEW MEDICAL GROUP, PC
  13. OLD HOOK MEDICAL ASSOCIATES, LLC
  14. OM MEDICAL CENTER, LLC
  15. PALISADES MEDICAL BILLING dba PALISADES MEDICAL ASSOCIATES
  16. PREMIER MEDICAL ALLIANCE LLC
  17. PREVENTION CLINICS LLC
  18. PRIMARY CARE MEDICINE LLC
  19. RAJITHA GUJJA MD LLC
  20. RIVERSIDE PEDIATRIC GROUP PC
  21. SHARAD SAHU MD
  22. SUMMIT AVENUE MEDICAL PA

ACO Participants in Joint Ventures Between ACO Professionals and Hospitals (annotated by asterisk [*]):

  1. ALLAM MEDICAL GROUP LLC*
  2. FEI YU*
  3. FOREST HEALTHCARE ASSOCIATES, PC*
  4. FRANK MASTRIANNO*
  5. GARY SCHWARTZ MD*
  6. HACKENSACK UNIVERSITY MEDICAL GROUP PC*
  7. INTEGRATED MEDICAL ASSOCIATES LLC*
  8. LHP NEW JERSEY MD SERVICES PC*
  9. MAGED BOUTROS*
  10. MEDICAL ASSOCIATES OF ENGLEWOOD PC*
  11. MONTCLAIR HOSPITAL LLC*
  12. MOUNTAINVIEW MEDICAL GROUP, PC*
  13. OLD HOOK MEDICAL ASSOCIATES, LLC*
  14. OM MEDICAL CENTER, LLC*
  15. PALISADES MEDICAL BILLING dba PALISADES MEDICAL ASSOCIATES*
  16. PREMIER MEDICAL ALLIANCE LLC*
  17. PREVENTION CLINICS LLC*
  18. PRIMARY CARE MEDICINE LLC*
  19. RAJITHA GUJJA MD LLC*
  20. RIVERSIDE PEDIATRIC GROUP PC*
  21. SHARAD SAHU MD*
  22. SUMMIT AVENUE MEDICAL PA*

ACO Governing Body:

  1. Dr. Peter Gross, Non-Voting Member, Chair 
  2. Dr. Morey Menacker, Voting Member, ACO provider/supplier, Forest Healthcare Associates PC
  3. Dr. Edward Gold, Voting Member, ACO provider/supplier, LHP New Jersey MD Services PC
  4. Dr. Azzam Baker, Voting Member, ACO provider/supplier, Riverside Pediatric Group PC
  5. Dr. Ihor Sawczuk, Voting Member, ACO provider/supplier, Hackensack University Medical Group PC
  6. Dr. Eric Avezzano, Voting Member, ACO provider/supplier, Premier Medical Alliance LLC
  7. Dr. Kenneth Faistl, Voting Member, ACO provider/supplier, Montclair Hospital LLC
  8. Dr. Michael Giuliano, Voting Member, ACO provider/supplier, Old Hook Medical Associates LLC
  9. Dr. Sharad Sahu, Voting Member, ACO Participant, Sharad Sahu MD
  10. Dr. Edward Prins, Voting Member, ACO provider/supplier, Summit Avenue Medical PA
  11. Mr. Bernard Bober, Voting Member, Medicare Beneficiary Representative
  12. Mr. Robert Garrett, Voting Member, Other - Hackensack Meridian Health
  13. Mr. Mark Sparta, Voting Member, Other – Hackensack Meridian Health


Key ACO Clinical and Administrative Leadership:

  1. ACO Executive: Dr. Morey Menacker
  2. Medical Director: Dr. Edward Gold
  3. Compliance Official: Mr. Thomas Flynn
  4. Quality Assurance/Improvement Official: Dr. Edward Gold

Associated Committees and Committee Leadership:

  1. Quality Assurance and Improvement Committee: Dr. Morey Menacker, Chair
  2. Compliance Committee: Dr. Sharad Sahu, Chair

Types of ACO Participants or Combinations of Participants That Formed the ACO:

  1. ACO professionals in a group practice arrangement
  2. Partnership or joint venture arrangement between hospitals and ACO professionals

SHARED SAVINGS AND LOSSES

Amount of Shared Savings/Losses:

  • Agreement period beginning 2012, Performance Year 1: $5,266,358 
  • Agreement period beginning 2012, Performance Year 2014: $2,832,988 
  • Agreement period beginning 2012, Performance Year 2015: $15,640,878

Shared Savings Distribution:

  • Agreement period beginning 2012, Performance Year 1
    • Proportion invested in infrastructure: 40%
    • Proportion invested in redesigned care process/resources: 10%
    • Proportion of distribution to ACO participatnts: 50%
  • Agreement period beginning 2012, Performance Years 2014
    • Proportion invested in infrastructure: 40%
    • Proportion invested in redesigned care process/resources: 10%
    • Proportion of distribution to ACO participatnts: 50%
  • Agreement period beginning 2012, Performance Year 2015
    • Proportion invested in infrastructure: 40%
    • Proportion invested in redesigned care process/resources: 10%
    • Proportion of distribution to ACO participatnts: 50%

PAYMENT RULE WAIVERS

  • No, our ACO does not utilize the SNF 3-Day Rule Waive

QUALITY PERFORMANCE RESULTS

2015 Quality Performance Results Table


Measure
Number

Measure Name

2015 Reporting Period

ACO

Performance Rate

Mean Performance

Rate (SSP-ACOs)

ACO-1

CAHPS: Getting Timely Care, Appointments, and Information

82.14

80.61

ACO-2

CAHPS: How Well Your Providers Communicate

92.69

92.65

ACO-3

CAHPS: Patients’ Rating of Provider

91.48

91.94

ACO-4

CAHPS: Access to Specialists

81.03

83.61

ACO-5

CAHPS: Health Promotion and Education

58.58

59.06

ACO-6

CAHPS: Shared Decision Making

75.33

75.17

ACO-7

CAHPS: Health Status/Functional Status

71.92

72.30

ACO-34

CAHPS: Stewardship of Patient Resources*

21.24

26.87

ACO-8

Risk Standardized, All Condition Readmission

15.06

14.86

ACO-35

Skilled Nursing Facility 30-Day All-Cause Readmission Measure (SNFRM)* Readmission

20.72

18.07

ACO-36

All-Cause Unplanned Admissions for Patients with Diabetes*

58.94

54.60

ACO-37

All-Cause Unplanned Admissions for Patients with Heart Failure*

80.13

76.96

ACO-38

All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions

63.18

62.92

ACO-9

Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)

1.28

1.11

ACO-10

Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8)

0.84

1.04

ACO-11

Percent of Primary Care Physicians who Successfully Meet Meaningful Use Requirements

80.34%

76.22%

ACO-39

Documentation of Current Medications in the Medical Record*

98.98%

84.07%

ACO-13

Falls: Screening for Future Fall Risk

74.92%

56.46%

ACO-14

Preventive Care and Screening: Influenza Immunization

76.61%

62.03%

ACO-15

Pneumonia Vaccination Status for Older Adults

63.58%

63.73%

ACO-16

Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-up

88.58%

71.15%

ACO-17

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

95.45%

90.16%

ACO-18

Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan

69.55%

45.25%

ACO-19

Colorectal Cancer Screening

70.42%

60.06%

ACO-20

Breast Cancer Screening

73.97%

65.67%

ACO-21

Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

88.35%

70.04%

ACO-40

Depression Remission at Twelve Months*

N/A

N/A

ACO-27

Diabetes Mellitus: Hemoglobin A1c Poor Control

14.18%

20.38%

ACO-41

Diabetes: Eye Exam*

49.65%

41.05%

ACO-28

Hypertension: Controlling High Blood Pressure

80.13%

69.62%

ACO-30

Ischemic Vascular Disease: Use of Aspirin or Another Antithrombotic

92.25%

83.82%

ACO-31

Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

97.91%

87.22%

ACO-33

Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)

90.21%

77.73%

CAHPS = Consumer Assessment of Healthcare Providers and Systems, PQI = Prevention Quality Indicator, LVSD = lef tventricular systolic dysfunction, ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CAD = coronary artery disease.

* = Measure required beginning Reporting Year 2015.

N/A = Reporting on the depression remission measure is not required for 2015, as indicated by N/A



2012 - 2014 Quality Performance Results Table

Quality Measure

2012 Reporting Period

2013 Reporting Period

2014 Reporting Period

Measure
Number

Performance Measure

ACO Performance Rate

Mean Perf Rate for All ACOs

ACO Performance Rate

Mean Perf Rate for All ACOs

ACO Performance Rate

Mean Perf Rate for All ACOs

ACO #1

Getting Timely Care, Appointments, and Information

79.96

81.79

81.50

81.48

76.73

80.13

ACO #2

How Well Your Doctors Communicate

92.10

92.84

93.30

92.96

92.37

92.39

ACO #3

Patients’ Rating of Doctor

91.11

91.86

91.58

92.06

90.97

91.58

ACO #4

Access to Specialists

84.74

85.11

86.50

85.12

87.11

83.97

ACO #5

Health Promotion and Education

54.01

56.61

55.85

58.38

60.24

58.29

ACO #6

Shared Decision Making

71.13

73.99

74.14

74.53

71.28

74.60

ACO #7

Health Status/Functional Status

71.96

70.35

73.84

71.12

69.22

71.10

ACO #8

Risk Standardized, All Condition Readmissions

16.33

15.42

15.52

14.90

16.43

15.15

ACO #9

ASC Admissions: COPD or Asthma in Older Adults

1.17

1.13

1.07

1.17

1.03

1.08

ACO #10

ASC Admission: Heart Failure

0.84

1.09

1.05

1.20

1.19

1.19

ACO #11

Percent of PCPs who Qualified for EHR Incentive Payment

34.92%

25.70%

69.01%

66.21%

77.63%

76.71%

ACO #12

Medication Reconciliation

88.10%

72.37%

87.38%

73.56%

93.54%

82.61%

ACO #13

Falls: Screening for Fall Risk

5.58%

28.27%

35.95%

39.57%

70.35%

45.60%

ACO #14

Influenza Immunization

50.17%

50.58%

66.78%

56.93%

79.78%

57.51%

ACO #15

Pneumococcal Vaccination

36.36%

48.62%

62.44%

54.76%

72.95%

55.03%

ACO #16

Adult Weight Screening and Follow-up

51.36%

5.39%

73.28%

61.61%

92.05%

66.75%

ACO #17

Tobacco Use Assessment and Cessation Intervention

79.67%

80.12%

9269.00%

84.01%

97.70%

86.79%

ACO #18

Depression Screening

26.58%

22.48%

35.31%

31.19%

66.85%

39.27%

ACO #19

Colorectal Cancer Screening

57.17%

50.21%

67.38%

59.30%

73.84%

56.14%

ACO #20

Mammography Screening

50.08%

62.23%

65.22%

62.05%

76.38%

61.41%

ACO #21

Proportion of Adults who had blood pressure screened in past 2 years

60.75%

71.56%

94.73%

74.25%

94.83%

60.24%

ACO #22

Hemoglobin A1c Control (HbA1c) (<8 percent)

74.78%

N/A

76.10%

N/A

79.47%

N/A

ACO #23

Low Density Lipoprotein (LDL) (<100 mg/dL)

61.20%

N/A

62.37%

N/A

N/A

N/A

ACO #24

Blood Pressure (BP) <140/90

71.43%

N/A

77.12%

N/A

76.32%

N/A

ACO #25

Tobacco Non Use

88.01%

N/A

87.29%

N/A

91.72%

N/A

ACO #26

Aspirin Use

68.23%

N/A

91.75%

N/A

97.73%

N/A

ACO #27

Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent)

15.52%

25.94%

14.58%

22.11%

9.60%

20.35%

ACO #28

Percent of beneficiaries with hypertension whose BP <140/90

67.23%

63.22%

78.23%

67.79%

82.01%

68.02%

ACO #29

Percent of beneficiaries with IVD with complete lipid profile and LDL control <100mg/dl

35.98%

52.02%

61.10%

55.44%

N/A

N/A

ACO #30

Percent of beneficiaries with IVD who use Aspirin or other antithrombotic

80.30%

72.60%

83.81%

76.35%

93.49%

80.79%

ACO #31

Beta-Blocker Therapy for LVSD

83.17%

79.60%

88.27%

79.82%

96.86%

82.71%

ACO #32

Drug Therapy for Lowering LDL Cholesterol

88.25%

N/A

79.93%

N/A

N/A

N/A

ACO #33

ACE Inhibitor or ARB Therapy for Patients with CAD and Diabetes and/or LVSD

77.66%

N/A

82.20%

N/A

88.59%

N/A

Note: ASC = ambulatory sensitive conditions, COPD = chronic obstructive pulmonary disease, PCP = primary care physician, EHR = electronic health record, IVD = ischemic vascular disease, LVSD = left ventricular systolic dysfunction, ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CAD = coronary artery disease.

For more information on how to interpret scores on the above quaility performance measures, see

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/MSSP-QM-Benchmarks.pdf

DISCLOSURE BY

HACKENSACK PHYSICIAN-HOSPITAL ALLIANCE ACO, LLC

(FOR PURPOSES OF MEDICARE FRAUD AND ABUSE WAIVER)
 

Hackensack Physician-Hospital Alliance ACO, LLC (the "ACO") seeks waiver protection under the federal Medicare Shared Savings Program for the following arrangement:

The ACO has entered into an arrangement with Hackensack University Medical Center ("HUMC"), as of April 1, 2016, whereby HUMC and its affiliates, HUMC Cardiovascular Partners, P.C. ("HUMCCP"), and Hackensack University Medical Group, P.C. ("HUMG"), and the cardiologists employed or otherwise engaged by HUMCCP and HUMG will provide on-call coverage and professional cardiology services to the ACO patients of HUMC (both in HUMC's emergency department and elsewhere, as needed).  The purposes of this arrangement are to improve accountability for the quality of care for the ACO's patients, by means of coordinated and integrated protocols and personnel, as well as to improve the efficiency, quality, and access to cardiac care for the ACO's chest pain patients at HUMC.  In particular, the arrangement is intended to ensure accessibility to consistent and coordinated high quality cardiac evaluation and treatment of the ACO's patients at HUMC.





 

Page Last Modified:  2/20/2017  7:35AM

 


close (X)